Interview with Patrik De Haes, Chief Executive Officer, ThromboGenics
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
Address: Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 (0) 16 75 13 10
Web: http://thrombogenics.com/
Thrombogenics NV is a Belgium-based biopharmaceutical company focused on the discovery and development of medicines for the treatment of eye disease, vascular disease and cancer. The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.
The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
Vincent Stephenne, managing director of Belgian CDMO BePharBel Manufacturing, highlights the company’s innovative approach to developing new galenic forms for existing molecules, its growth trajectory thus far, and his future…
Christophe Van Damme, vice president and general manager of Perrigo Belgium and Luxembourg, shines a light on the transformation for Perrigo since its acquisition of Omega Pharma in 2015. Van…
Veronique Walsh, general manager of Bristol Myers Squibb for Belgium, the Netherlands, and Luxembourg (Benelux), recently spoke to PharmaBoardroom about her diverse career path, transitioning from medical doctor to pharmaceutical…
In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally…
Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the…
Stakeholders from the Belgian parallel trade industry outline how their activities are helping to solve medicine shortages in Europe and ensure patients have access to the medicines they need. They…
Geert Van Hoof, founding general manager of Chiesi Belgium, shares the exciting milestones of the company’s first decade in Belgium, including their stunning year-on-year double-digit growth, their market leadership in…
Tanguy Schmitz, president of the Belgian Association of Parallel Importers & Exporters (BAPIE) outlines some of the recent work that the parallel distribution industry to ensure the supply of medicines…
Four Belgium country managers for some of the world’s largest pharma companies give their words of wisdom for women starting out in the industry. “Focus on your strengths” Sonja…
Filip Van de Vliet and Gérard Lefèbvre of Alter Pharma Group discuss the value that parallel importing is bringing to Belgian patients and the evolving relationship between parallel importers and…
Marijke Eyssen of the Belgian Health Care Knowledge Centre (KCE) introduces the institution’s mission, core values, how it chooses areas of research, and the crucial work the KCE does in…
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
See our Cookie Privacy Policy Here
